Evogene Ltd.EVGN
Price (close)
$0.42
Market cap
$6.7M
P/E
—
Revenue (FY)
$3.9M
Net income
-$8.5M
Dividend yield
—
1-year total return
-61.8%
Net margin
-220.2%
Revenue growth
-30.9%
Debt / equity
—
What Evogene Ltd. does.
multiple-parameters, for drug development and ag-chemicals, by utilizing ChemPass AI, our computational generative AI engine.
industries entails the identification of successful candidates from among a large number of potential prospects. A major barrier
in small molecule discovery is the limited exploration of chemical space. Most candidates come from a narrow, well-charted domain, restricting
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $930,000 | $1.7M | $3.0M | $5.6M | $3.9M |
| Net income | -$23.4M | -$27.8M | -$26.6M | -$23.9M | -$16.5M | -$8.5M |
| Free cash flow | -$20.2M | -$25.6M | -$24.8M | -$22.2M | -$20.3M | -$13.6M |
More on EVGN.
- Evogene Ltd. summary
- Evogene Ltd. financial statements
- Evogene Ltd. key metrics
- Evogene Ltd. health scores and style box
- Evogene Ltd. earnings
- Evogene Ltd. dividends
- Evogene Ltd. valuation
- Evogene Ltd. ownership and insiders
- Evogene Ltd. peers
Figures from Evogene Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.